Skip to content

Advertisement

  • Poster presentation
  • Open Access

Recent advances in adoptive cancer immunotherapy in china

  • 1
Journal for ImmunoTherapy of Cancer20153 (Suppl 2) :P64

https://doi.org/10.1186/2051-1426-3-S2-P64

  • Published:

Keywords

  • Advanced Gastric Cancer
  • Pancreatic Adenocarcinoma
  • Cancer Immunotherapy
  • Proliferation Ability
  • Uniform Criterion

Background

Cytokine-induced killer (CIK) cells have been extensively used in treatment of cancer patients in China. Clinical trials demonstrated that there were markedly decreased tumor nodules in size in a patient with advanced pancreatic adenocarcinoma following four cycles of CIK cell infusion and thus the patient had a longer progression-free survival. Moreover, immunotherapy with CIK cells in combination with chemotherapy had more potential benefits including longer progression-free survival and overall survival in patients with cancer such as advanced gastric cancer and non-small-cell lung cancer as compared with chemotherapy alone. In addition, dendritic cell (DC)-CIK cells have increased proliferation ability, cytokine secretion and anti-tumor activity as compared with CIK cells alone.

Results

A clinical trial showed that immunotherapy with tumor lysate-pulsed DC-CIK cells could significantly increase overall survival rates than no treatment control in renal cancer carcinoma patients. Thus, nowadays, DC-CIK cells have also been extensively used in treatment of cancer patients in China although the efficacy and mechanisms of adoptive cell transfer therapy with DC-CIK cells remains to be determined. In one word, the accumulation of basic researches and clinical studies related to cancer immunotherapy with CIK and DC-CIK cells has confirmed their safety and feasibility in treating malignant diseases. However, at present, there are still no uniform criteria or large-scale preparations of CIK and DC-CIK cells and the overall clinical response is difficult to evaluate due to lack of practical and appropriate criteria.

Conclusions

Large-scale, controlled, grouped, and multi-center clinical trials on CIK and DC-CIK cell-based immunotherapy should be conducted in the near future.

Declarations

Acknowledgements

Supported by “Taishan Scholar” special fund from Shandong Government, China.

Authors’ Affiliations

(1)
Ludong University, Lexington, SC, USA

Copyright

Advertisement